NeuroPace opened at $12.52, in line with its previous close of $12.52. In the last trading session, the stock traded between $12.09 and $12.67. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in NeuroPace is now worth
$ 85.89
Resulting in a loss of
$ 14.11 (14.11%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.50 (-3.96%)
Day High
$12.67
Day Low
$12.09
Day Open
$12.52
Prev Close
$12.52
Volume
87,454
1W Return
-9.75%
1M Return
-7.54%
3M Return
-20.23%
6M Return
-23.27%
1Y Return
-10.87%
Fundamentals
Market Cap ($ Mn)
413
PE Ratio
-
PB Ratio
41.63
PEG Ratio
-
ROE
-120.23%
ROCE
-19.15%
EPS (TTM)
$-0.18
Investment Returns
1 Week
-9.75%
1 Month
-7.54%
3 Months
-20.23%
6 Months
-23.27%
9 Months
-17.42%
Financials
Quarterly
All values in $ Mn
22.5
Mar 25
23.5
Jun 25
27.4
Sep 25
26.6
Dec 25
22.1
Mar 26
22.8
Jun 26
Updates
13Nov
NeuroPace cuts FY26 sales guidance to $91M-$92M, misses estimates
NeuroPace lowered FY2026 sales guidance to $91.000M-$92.000M. New guidance misses analyst consensus of $100.321M. Q3 revenue fell 15.55% YoY to $23.100M. EPS loss narrowed to $(0.10), beating estimates.
Today
1Sep
NeuroPace to host fireside chat at Wells Fargo healthcare conference
NeuroPace management to speak at Wells Fargo 21st Annual Healthcare Conference. Fireside chat scheduled for Tuesday, September 8, at 8:00 am EDT. Live webcast and replay available on investor website.
NeuroPace Inc raised its FY2026 sales guidance to $99.500M-$101.500M, beating the $99.913M estimate. The update reflects strong demand for its RNS System and increased visibility into recurring revenue streams.
3mo ago
12Aug
NeuroPace Q2 EPS beats estimates as revenue rises 17% to $22.8 million
NeuroPace reported Q2 2026 EPS of $(0.18), beating the $(0.20) estimate, and revenue of $22.826 million, exceeding the $22.654 million forecast. The company narrowed its GAAP net loss to $6.2 million from $10.0 million in the prior year, driven by 21.3% growth in RNS System revenue.
3mo ago
29Jul
NeuroPace to submit SIR after FDA rejects IGE indication supplement
NeuroPace faces a regulatory hurdle as the FDA finds its PMA Supplement for expanding the RNS System indication to idiopathic generalized epilepsy not approvable. The company plans to submit a Submission Issue Request and amend its application with additional data from the NAUTILUS trial, which showed significant seizure reduction.
3mo ago
23Jul
Mizuho initiates coverage on NeuroPace with Outperform rating
Mizuho analyst Anthony Petrone has initiated coverage on NeuroPace with an Outperform rating and a price target of $22.
